March 22, 2017: How much should the public trust Amgen’s latest data regarding Repatha and its ability to lower cholesterol and reduce the chance of death from cardiovascular-related events.
March 22, 2017: Want to be a billionaire. Then maybe you should do the same things billionaires do. Keith Speights, writing for The Motley Fool, looked at the stocks the country’s wealthiest investors put their money into. Here’s a peek.
March 22, 2017: The U.S. Patent Trial and Appeal Board rejected a patent suit against Cambridge, CA based Biogen leveled by Texas hedge fund manager Kyle Bass.
March 22, 2017: With biotech stocks struggling to gain a foothold, investors are always looking for a bit of information that hints at potential gains in marketshare. Biotech analyst Edward Nash selected five stocks that are expecting major catalysts over the next six to nine months.